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ABSTRACT
Objective: To describe the compassionate use of interleukin-7 (IL-7) for treatment of progressive
multifocal leukoencephalopathy (PML) in the setting of idiopathic CD81 greater than CD41
lymphocytopenia.
Methods: A 66-year-old HIV-seronegative man presented with progressive language dysfunction.
MRI showed hyperintense lesions in the left hemispheric white matter with mild contrast enhance-
ment. A brain biopsy performed 4 months after symptom onset established the diagnosis of PML.
The patient had profound lymphocytopenia with absolute lymphocyte count (ALC) at 168 cells/
mL, 87 CD41 T cells/mL, and 7 CD81 T cells/mL. There was no evidence of hematologic malig-
nancy or rheumatologic disease.
Results: The patient received 3 intramuscular injections of IL-7 at a dose of 10 mg/kg per week
with no adverse effects. ALC peaked at 595 cells/mL, CD41 T cells at 301 cells/mL, and CD81
T cells at 34 cells/mL 3 weeks after completion of treatment. His lesions on MRI stabilized and
neurologic examination mildly improved. JCV-specific T-cell responses measured by intracellular
cytokine staining were not altered after treatment with IL-7 but there was a marked increase in
regulatory T cells.
Conclusion: This case further supports the investigational use of IL-7 in patients who develop
PML in the setting of ICL.
Classification of evidence: This study provides Class IV evidence that for patients with ICL and
PML, IL-7 improves PML-related-outcomes. The study is rated Class IV because it is a case
report. Neurol Neuroimmunol Neuroinflamm 2016;3:e213; doi: 10.1212/NXI.0000000000000213
GLOSSARY
IL-7 5 interleukin-7; IRIS 5 immune reconstitution inflammatory syndrome; JCV 5 JC polyomavirus; Lip1/Cr 5 lipid 1/creatine;
MRS5magnetic resonance spectroscopy;NIHSS5NIHStroke Scale;PML5 progressivemultifocal leukoencephalopathy;TReg5
regulatory T cell.
Progressive multifocal leukoencephalopathy (PML), caused by the JC polyomavirus (JCV), is a
demyelinating disorder for which there is no cure.1 Upon review of the literature, 12 previous
cases of PML in the setting of idiopathic CD41 lymphocytopenia (ICL) have been reported.2
ICL is diagnosed when absolute CD41 T-cell counts are less than 300 cells/mL on more than
one occasion in the absence of other causes of immunocompromised state.3 Several medica-
tions have been utilized for treatment of PML in patients with ICL, but none has proven
efficacious.4 However, recovery of anti-JCV T-cell responses correlates with PML survival.5
Interleukin-7 (IL-7) is a multifunctional cytokine that is essential for T-cell proliferation,
modulation of peripheral T-cell subsets, and enhancement of T-cell functionality, including
virus-specific immunity.6 Recently, IL-7 has been used in Europe for treatment of PML in the
setting of ICL and secondary lymphocytopenia with normal CD81 T-cell counts.7–9 We
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report the case of a patient with lymphocyto-
penia affecting CD81 more than CD41 T
cells as well as B cells who developed PML
and was treated with IL-7. We studied radi-
ologic markers of disease evolution using
magnetic resonance spectroscopy (MRS)
and perfusion MRI and monitored his
immune response to JCV using intracellular
cytokine staining.
CASE REPORT A 66-year-old man with a history of
hypertension and hypercholesterolemia began to
notice subtle problems with language. One month
later, an outpatient brain MRI was interpreted as
subacute left temporo-parietal stroke, leading to his
hospitalization at our institution. Complete blood
count (CBC) on admission showed 6,700
leukocytes with 5.9% lymphocytes corresponding
to an absolute lymphocyte count (ALC) of
395 cells/mL. He was discharged on antiplatelet and
statin therapies, but his symptoms progressed over the
next 2 months as he developed worsening word-
finding difficulties, paraphasic errors, and trouble
reading and writing. A repeat brain MRI was
interpreted as increased edema in the left
hemisphere with possible cortical enhancement. He
was again hospitalized and CSF examination showed
3 leukocytes, 1,045 erythrocytes, protein 36 mg/dL,
and glucose 77 mg/dL. Herpes simplex virus 1 and 2
DNA was not detected via PCR. MRS revealed
an elevated choline peak in the left parietal white
matter suggestive of malignancy. CBC on admission
showed 4,700 leukocytes with 7% lymphocytes
corresponding to an ALC of 329 cells/mL.
The patient underwent elective stereotactic brain
biopsy of the left temporo-parietal brain lesion
1 month later, for presumptive diagnosis of glioma.
Histopathologic examination revealed marked reac-
tive gliosis, scattered bizarre astrocytes with enlarged
nuclei, and numerous SV40-positive nuclear inclu-
sions, consistent with the diagnosis of PML. There
was infiltration by CD31 T and CD201 B lympho-
cytes, as well as numerous CD681 macrophages. He
was subsequently evaluated in our Neuroinfectious
Diseases Clinic, at which time his neurologic exami-
nation showed a mixed expressive greater than recep-
tive aphasia (NIH Stroke Scale [NIHSS] score 5 1).
Brain MRI 1 month after biopsy showed mildly
enhancing left hemispheric PML lesions and MRS
revealed a lipid 1/creatine (Lip1/Cr) ratio .1.5 in
the left temporo-parietal lesion indicating a 79% like-
lihood of immune reconstitution inflammatory syn-
drome (IRIS).10 Arterial spin labeling MRI showed
no evidence of hyperperfusion around the PML le-
sions, consistent with a favorable outcome.11 Sero-
logic tests were negative for HIV-1, HIV-2,
hepatitis, antinuclear antibodies, dsDNA, ribosomal
P antibody, and Sjögren antibodies. The erythrocyte
sedimentation rate, angiotensin-converting enzyme,
rheumatoid factor, and complement levels were
within normal limits. Immunoglobulin (Ig) studies
were normal (IgG total 1,331 mg/dL, IgA 196 mg/
dL, and IgM 166 mg/dL). Initial T-cell subsets re-
vealed profound lymphocytopenia (ALC 168 cells/
mL, CD41 count 87 cells/mL, CD81 count 7
cells/mL, CD4/CD8 ratio 12.4, and CD191/
CD201 counts 4–8 cells/mL). Based upon the
absence of history of recurrent infections, inflamma-
tory or autoimmune disorders, malignancy, recent
surgery, or bone marrow suppressing medications,
the most likely diagnosis was believed to be idiopathic
lymphocytopenia. Retrospective review of past re-
cords indicated that this patient already had a low
ALC 8 years (590 cells/mL) and 4 years (310 cells/
mL) prior to the onset of PML symptoms. JCV DNA
Figure 1 Evolution of MRI findings during interleukin (IL)–7 therapy
Axial fluid-attenuated inversion recovery images from (A, B) pre-IL-7 and (C, D) 2weeks post-IL-
7 MRI of the brain demonstrate stable left hemispheric subcortical progressive multifocal leu-
koencephalopathy (PML) lesions, but a new, small, asymptomatic left cerebellar lesion (white
arrow), (E, F) which remains unchanged on the most recent MRI performed 16 weeks after
IL-7 therapy.
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in CSF was not detected by PCR, but quantitative
PCR in DNA extracted from paraffin sections of
brain tissue showed 5.2 million JCV copies/slide.
This confirmed the diagnosis of PML in the setting
of idiopathic lymphocytopenia involving CD81
more than CD41 T cells.
METHODS Standard protocol approvals, registrations,
and patient consents. We obtained an emergency investiga-
tional new drug approval from the Food and Drug Administra-
tion for the compassionate use of IL-7 (CYT107, RevImmune,
Paris, France). Single-patient use institutional review board
approval was obtained from the Beth Israel Deaconess Medical
Center (BIDMC) Committee on Clinical Investigations. A
Materials Transfer Agreement between RevImmune and
BIDMC was negotiated. Written informed consent was
obtained from the patient. CYT107 was dispensed by the
BIDMC research pharmacy and administered in the BIDMC
Infusion Center. We used the NIHSS to assess for changes in
neurologic status.
RESULTS A single cycle of IL-7 was administered
intramuscularly once weekly for 3 consecutive
weeks at a dose of 10 mg/kg with no adverse effects.
The patient’s neurologic examination showed a stable
moderate mixed aphasia (NIHSS 5 1) with no new
neurologic deficits compared to a pre-IL-7
examination. Brain MRI 2 weeks post IL-7 showed
less conspicuous but persistently enhancing left
hemispheric PML lesions, and a new, small,
enhancing left cerebellar lesion (figure 1). MRS was
unchanged in the left temporo-parietal region, and
the new left cerebellar enhancing lesion had a Lip1/
Cr ratio #1.5.10 CSF JCV DNA was again
undetectable by PCR 3 weeks post IL-7. From the
first measurement of T-cell subsets 2 months pre-IL-
7 to repeat T-cell subsets 3 weeks post IL-7, there was
an increase in ALC from 168 to 595 cells/mL, CD41
T cells from 87 to 301 cells/mL, and CD81 T cells
from 7 to 34 cells/mL (figure 2). Twenty-nine weeks
after IL-7 therapy, there was a decline in ALC to 242
cells/mL, CD41 T cells to 87 cells/mL, and CD81
T cells to 4 cells/mL, back to pre-IL-7 baseline levels.
Over 6 months, the B cells remained stably low,
ranging from 4 to 41 cells/mL. The leukocyte count
fluctuated significantly throughout IL-7 treatment,
but always remained in the normal range (4.5–9.4
K/mL). JCV-specific CD41 and CD81 T-cell
responses were measured by intracellular cytokine
staining 1 week pre-IL-7, and they were unaltered
1 week post-IL-7 treatment. Interestingly, IL-7
induced a 10-fold increase in the overall percentage
of regulatory T cells (TRegs) (figure 3). While recent
studies have shown that IL-2 is the main factor
driving the development of TRegs, IL-7 can also
mediate intrathymic TReg development.6 On the
Figure 2 Evolution of blood cell counts during interleukin (IL)–7 therapy
The leukocyte count is displayed using the linear y-axis on the right side, while the absolute lymphocyte counts, T-cell, and B-
cell subsets are displayed on the logarithmic y-axis on the left side. The x-axis displays time in months. Time of onset of pro-
gressive multifocal leukoencephalopathy (PML) symptoms (PML onset), neurology admissions (Neuro admit 1 and 2), lumbar
puncture (LP), and IL-7 injections are indicated by downward arrows along the x-axis. ALC (c) 5 calculated absolute lym-
phocyte counts based on total leukocyte counts and lymphocyte percentage; ALC 5 absolute lymphocyte count measured
by the clinical laboratory; CD4 5 CD41 T cells; CD8 5 CD81 T cells; CD19 5 CD191 B cells; CD20 5 CD201 B cells;
WBC 5 leukocyte count.
Neurology: Neuroimmunology & Neuroinflammation 3
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
patient’s most recent MRI 16 weeks after treatment,
the PML lesions remained unchanged except for the
disappearance of contrast enhancement. There was
also a decrease in the Lip1/Cr ratio ,1.5,
indicating resolution of IRIS. The patient was
started on trimethoprim/sulfamethoxazole for
prevention of other opportunistic infections. On his
7-month follow-up post IL-7 administration, 13
months after onset of PML, his neurologic
examination showed mild improvement in speed
and fluency of speech (NIHSS 5 1).
DISCUSSION Effective treatments for PML do not
exist, and standard therapies to increase CD41 and
CD81 T cells or improve immune function in ICL
are not commercially available. One of the key drivers
of T-cell homeostasis and function is IL-7, and
preliminary data indicate that this cytokine may
augment virus-specific immune responses, which
could provide clinical benefit for immunosuppressed
individuals, including those with ICL.6 Due to the
often fatal outcome of PML, our patient was treated
with intramuscular injections of IL-7 with the aim to
restore overall immune function. Uniquely, our
patient had multiple lymphocytopenias with low
CD81 T cells, CD41 T cells, and B cells. The
effects of IL-7 were selective with regard to T-cell
subsets as the CD41 T-cell population expanded to
a greater extent than CD81 T cells. This is relevant
since CD81 T cells are thought to be most important
in containing JC virus. As expected, there was no
effect on B-cell counts. Of note, treatment with IL-
7 was well-tolerated, with no IRIS during 7 months of
follow-up. CD41 T-cell counts remained elevated for
approximately 3 months after treatment with IL-7.
Given that the half-life of IL-7 is 7–23 hours, our
results suggest that the biological effects of IL-7 on
blood cell counts continue after serum cytokine levels
return to baseline, usually 72 hours after injection.6
Thus, in the present case, investigational use of IL-7
led to rapid increase in overall CD41 T-cell counts
and was associated with clinical benefit. Since the
patient remains alive more than 1 year from PML
onset, he is considered a PML survivor, and is
expected to have a favorable long-term clinical
outcome.12 Further prospective studies of IL-7 for
treatment of PML in patients with ICL are warranted.
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